Golimumab for rheumatoid arthritis (Q24240895)

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Infliximab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Rheumatoid arthritis. Treatment of early disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

New cytokine targets in inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Quality of life in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Etanercept for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Rituximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Anakinra for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Work disability in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

Treatment of rheumatoid arthritis: we are getting there

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008341

7 January 2021